Allogeneic Bone Paste Versus Allogeneic Bone Powder
Allogeneic Bone Paste Versus Allogeneic Bone Powder
Autogenous bone graft has been considered the gold standard in Guided Bone Regeneration (GBR)
 technique used for bone augmentation. However, there are disadvantages associated with
 autograft use such as limited amount of available bone and increased morbidity for the
 patient at the sampling site. Several biomaterials have been used as a replacement of the
 autogenous bone. Viral-inactivated bone allograft powder is an alternative that has proven
 efficacy and tolerance. This study aims to assess the non-inferiority of viral-inactivated
 allogeneic bone paste compared to a viral-inactivated cortico-cancellous allogenic bone
 powder in achieving the ideal bone volume.
Inclusion Criteria:

 1. Patient aged ≥ 18 years old

 2. Patient able to read, understand and give written consent to participate in the study

 3. Patient affiliated with a social security system or beneficiary of such a system

 4. Partially edentulous patient with 1 to 2 intercalary missing teeth or a terminal gap
 with distal vertical and lateral support bone volume

 5. Presence of a bone deficit requiring horizontal and / or vertical bone augmentation
 (stage 4 or 5 of the Benic and Hammerle classification) treated by GBR for delayed
 placement of up to 4 dental implants

 6. Possibility of acquisition by CBCT for the required protocol visits

 Exclusion Criteria:

 1. General contraindication to bone graft and implant surgery

 2. Pregnant woman or planned pregnancy during the study period or breast-feeding woman;

 3. Patient who has had a bone augmentation by GBR during the previous 12 months, in the
 area targeted for filling with the allogeneic material

 4. Patient who received less than 3 months ago a CBCT acquisition at the operative site

 5. Patient simultaneously requiring more than one GBR augmentation in the same quadrant

 6. Patient with signs of local infection at the targeted graft site

 7. Systemic, metabolic or autoimmune disease that may adversely affect healing of soft
 and bone tissue (eg, unbalanced type 1 or type 2 diabetes)

 8. Use of treatments (chemotherapy or radiotherapy) or drugs (bisphosphonates, chronic
 steroids) known to potentially interfere with tissue healing

 9. Patient presenting a dental plaque objectified by an oral examination (Loe SILNESS ≥ 2
 on more than 50% of the dental surfaces)

 10. Patient smoker of more than 10 cigarettes a day

 11. Any other condition that, in the investigator's opinion, would be detrimental to the
 safety of the patient or fail to meet the requirements of the protocol